Forest Laboratories has completed its Phase III clinical trials with Synapton (sustained-release physostigmine), an acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.
The six-month, double-blind, placebo-controlled trial significantly demonstrated the efficacy of Synapton, using both the ADAS-Cog and the CIBIC plus measures of primary clinical end-points, said Howard Soloman, president of Forest Laboratories.
He added that the company hopes to file a New Drug Application for Synapton by the end of its fiscal year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze